Project Grant R15CA242344
- This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $631,492 to support research at the University of Kentucky Research Foundation aimed at identifying nicotinamide N-methyltransferase (NNMT) as a new target to treat triple-negative breast cancer (TNBC). The 5-year project, awarded on April 7, 2025 and scheduled for completion by March 31, 2030, will: Define how NNMT promotes anchorage-independent growth and protects TNBC cells...
- The National Cancer Institute (NCI), under the federal Cancer Biology Research grant program (CFDA 93.396), awarded a $218,089 Project Grant to the University of California, Santa Barbara (UCSB) to develop and evaluate a novel chimeric antigen receptor macrophage (CAR-M) immunotherapy for the treatment of triple-negative breast cancer (TNBC). The project, titled "RAC-Enhanced Chimeric Antigen Receptor-Macrophage (RACE-CAR-M) Immunotherapy for Triple Negative Breast Cancer," aims to...
- Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $151,040 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective January 16, 2026, with completion targeted for July 31, 2028. This award supports a research training and development initiative focused on investigating the role of interferon gamma (IFNγ) in promoting metastasis and immune evasion in triple negative breast cancer (TNBC). The project comprises two primary...
- Federal Project Grant Award Summary The University of Tennessee Health Science Center received a $658,561 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective August 7, 2025, with a completion date of July 31, 2030. This award supports research focused on targeted MDM2 (Murine Double Minute 2) degradation as an improved therapeutic strategy for triple-negative breast cancer (TNBC). The project centers on optimization and...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $403,686 Project Grant to Cleveland Clinic Lerner College of Medicine of Case Western Reserve University on April 7, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393). The research project, titled "Discerning the Role of CDK10 in Driving Aggressiveness and Disparities of Triple Negative Breast Cancer," will be conducted through March 31, 2028, at the awardee's Cleveland, Ohio...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $135,993 Project Grant from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) effective December 1, 2025, with completion anticipated by May 31, 2027. The award funds investigative research examining the role of the Abelson (ABL) kinase-regulated hypoxia inducible factor-1 alpha (HIF-1A) and transcriptional co-activator with PDZ-binding motif (TAZ) signaling...
- This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
- This federal Project Grant award, provided by the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), is funding research at the University of Texas Southwestern Medical Center (UT Southwestern) to define the role of the RCOR2 gene in hypoxia-induced immune evasion and its potential therapeutic applications for triple-negative breast cancer. The $1.64 million award, effective from June 1, 2024 through May 31, 2027, will support...
- Federal Grant Award Summary The University of Kansas Medical Center Research Institute, Inc. received a $398,544 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), awarded on April 8, 2026, with completion targeted for March 31, 2028. This award funds pre-clinical evaluation of PRT3789, a highly selective SMARCA2 degrader, to address therapy-resistant triple-negative breast cancer (TNBC). The research will characterize molecular mechanisms...
CAPER, A NEW REGULATOR OF DNA DAMAGE AND REPAIR IN TRIPLE NEGATIVE BREAST CANCER - ABSTRACT TRIPLE NEGATIVE BREAST CANCER (TNBC) HAS THE POOREST CLINICAL OUTCOME AMONGST ALL BREAST CANCER SUBTYPES. TNBC LACKS THE EXPRESSION OF THE THREE MAJOR RECEPTORS FOUND IN OTHER SUBTYPES (ESTROGEN RECEPTOR [ER], PROGESTERONE RECEPTOR, AND/OR HORMONE EPIDERMAL GROWTH FACTOR RECEPTOR-2) MAKING THIS CANCER PARTICULARLY CHALLENGING WITH REGARDS TO TREATMENT MODALITIES. NOVEL TARGETED TREATMENTS THAT COULD KILL TNBC CELLS OR SENSITIZE THEM TO CHEMO- AND RADIATION THERAPIES ARE HIGHLY COVETED TO INCREASE SURVIVAL OF THESE PATIENTS. DUE TO ITS FAST PROLIFERATIVE RATE, TNBC RELIES HEAVILY ON DNA REPAIR MECHANISMS FOR ITS SURVIVAL AND PROTEINS INVOLVED IN THIS IMPORTANT CHECKPOINT ARE ATTRACTIVE TARGETS FOR CANCER TREATMENT. CAPER (RBM39) PROTEIN WAS RECENTLY SHOWN TO BE OVEREXPRESSED IN BREAST CANCER SPECIMENS COMPARED TO NORMAL BREAST TISSUES. WHILE CAPER KNOCKDOWN INHIBITS BREAST CANCER CELL GROWTH, ITS ROLE ON DNA DAMAGE AND REPAIR MECHANISMS IN BREAST CANCER AND ITS ROLE IN TNBC PROGRESSION AND RESPONSE TO CHEMO- AND RADIATION THERAPIES REMAIN COMPLETELY UNEXPLORED. OUR PRELIMINARY DATA DEMONSTRATE THAT KNOCKDOWN OF CAPER EXPRESSION IN TNBC CELLS INCREASES DNA DAMAGE AS REFLECTED BY INCREASED PHOSPHORYLATION OF H2AX AND ATM. THE DECREASED TOTAL CELL NUMBER AND INCREASED CASPASE-3/7 CLEAVAGE OBSERVED FOLLOWING CAPER KNOCKDOWN IN MDA-MB-231 AND BT549 TNBC CELLS IS SUGGESTIVE OF INSURMOUNTABLE DNA DAMAGE LEADING TO PROGRAMMED CELL DEATH (APOPTOSIS). THE EFFECT OF CAPER KNOCKDOWN ON DNA DAMAGE IN TNBC CELLS WAS CELL CYCLE-INDEPENDENT AND SELECTIVE TO CANCER CELLS, AS NON- TUMORIGENIC CELLS LACK THE EXPRESSION OF CAPER AND REMAIN UNAFFECTED FOLLOWING DELIVERY OF LENTIVIRAL CAPER SHRNAS. OUR PRELIMINARY RESULTS ALSO REVEALED THAT DNA REPAIR PROTEINS RAD-51, C-ALB AND RB WERE SIGNIFICANTLY DOWNREGULATED IN TNBC FOLLOWING CAPER KNOCKDOWN. WE POSIT THAT CAPER OVEREXPRESSION IN TNBC PLAYS AN IMPORTANT ROLE IN PROTECTION AGAINST DNA DAMAGE BY OPTIMIZING DNA REPAIR PATHWAYS. THE CURRENT PROPOSAL BUILDS ON OUR PREVIOUS WORK AND PRELIMINARY RESULTS AND AIMS TO DELINEATE THE ROLES OF CAPER IN BASAL DNA DAMAGE/REPAIR PATHWAYS AND TO DETERMINE ITS CLINICAL RELEVANCE IN TNBC GROWTH USING BOTH IMMUNOCOMPROMISED (XENOGRAFT) AND IMMUNOCOMPETENT (SYNGENEIC) ORTHOTOPIC MOUSE MODELS (AIM 1). IMPORTANTLY, WE WILL ALSO USE THESE TNBC CELLS AND MOUSE MODELS TO TEST THE UNEXPLORED ROLE OF CAPER IN THE RESPONSE TO DNA DAMAGING CHEMO- AND RADIATION THERAPIES IN BOTH IN VITRO AND IN VIVO SETTINGS (AIM 2). THE CURRENT PROPOSAL WILL VALIDATE THE ROLE OF CAPER AS AN IMPORTANT SIGNALING MOLECULE IN THE PROGRESSION OF TNBC AS WELL AS RESPONSE TO DNA DAMAGE USING CLINICALLY RELEVANT MODELS THAT ALSO INCORPORATE IMMUNE SURVEILLANCE AND WILL BE INSIGHTFUL IN THE FURTHER DEVELOPMENT OF TARGETED THERAPIES FOR THE TREATMENT OF TNBC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $0 | 4/8/26 | ||
| Not listed | $435.0k | 9/21/22 | ||
| Not listed | $435.0k | 9/21/22 |